Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Cash & Equivalents: 2017-2025

Historic Cash & Equivalents for Crinetics Pharmaceuticals (CRNX) over the last 8 years, with Sep 2025 value amounting to $110.9 million.

  • Crinetics Pharmaceuticals' Cash & Equivalents fell 65.05% to $110.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $110.9 million, marking a year-over-year decrease of 65.05%. This contributed to the annual value of $264.5 million for FY2024, which is 370.75% up from last year.
  • Crinetics Pharmaceuticals' Cash & Equivalents amounted to $110.9 million in Q3 2025, which was down 90.76% from $1.2 billion recorded in Q2 2025.
  • In the past 5 years, Crinetics Pharmaceuticals' Cash & Equivalents registered a high of $1.3 billion during Q1 2025, and its lowest value of $30.9 million during Q3 2022.
  • For the 3-year period, Crinetics Pharmaceuticals' Cash & Equivalents averaged around $379.1 million, with its median value being $264.5 million (2024).
  • Its Cash & Equivalents has fluctuated over the past 5 years, first plummeted by 83.11% in 2022, then spiked by 861.14% in 2024.
  • Over the past 5 years, Crinetics Pharmaceuticals' Cash & Equivalents (Quarterly) stood at $201.2 million in 2021, then slumped by 83.11% to $34.0 million in 2022, then soared by 65.42% to $56.2 million in 2023, then spiked by 370.75% to $264.5 million in 2024, then slumped by 65.05% to $110.9 million in 2025.
  • Its Cash & Equivalents was $110.9 million in Q3 2025, compared to $1.2 billion in Q2 2025 and $1.3 billion in Q1 2025.